➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Baxter
Colorcon
McKesson
AstraZeneca

Last Updated: September 25, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BALOXAVIR MARBOXIL

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Baloxavir Marboxil

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03629184 ↗ Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms Not yet recruiting Hoffmann-La Roche Phase 3 2018-11-16 This study will evaluate the safety, pharmacokinetics, and efficacy of baloxavir marboxil compared with oseltamivir in a single influenza episode in otherwise healthy pediatric participants (i.e., 1 to <12 years of age) with influenza-like symptoms.
NCT03653364 ↗ Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms Not yet recruiting Hoffmann-La Roche Phase 3 2018-12-13 This study will evaluate the safety, pharmacokinetics and efficacy of baloxavir marboxil in healthy pediatric participants from birth to <1 year with influenza like symptoms
NCT03684044 ↗ Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza Not yet recruiting Hoffmann-La Roche Phase 3 2018-11-30 This study will evaluate the efficacy, safety, and pharmacokinetics of baloxavir marboxil in combination with a standard-of-care (SOC) neuraminidase inhibitor (NAI) (i.e., oseltamivir, zanamivir, or peramivir) compared with a matching placebo in combination with a SOC NAI in hospitalized patients with influenza.
NCT03959332 ↗ Study to Assess the Pharmacokinetics, Safety and Tolerability of Baloxavir Marboxil in Healthy Chinese Participants Not yet recruiting Shionogi N/A 2019-06-04 This study will evaluate the pharmacokinetics, safety and tolerability of a single oral dose of baloxavir marboxil (40 mg or 80 mg) in healthy Chinese participants.
NCT03959332 ↗ Study to Assess the Pharmacokinetics, Safety and Tolerability of Baloxavir Marboxil in Healthy Chinese Participants Not yet recruiting Hoffmann-La Roche N/A 2019-06-04 This study will evaluate the pharmacokinetics, safety and tolerability of a single oral dose of baloxavir marboxil (40 mg or 80 mg) in healthy Chinese participants.
NCT03969212 ↗ Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households Not yet recruiting Hoffmann-La Roche Phase 3 2019-05-30 Otherwise healthy index patients (IP) are randomized to either baloxavir marboxil or placebo if their influenza symptoms onset was within 48 hours of screen. Their households are enrolled within 24 hours of randomization if at least 2 household contacts (HHC) have not received influenza vaccine within 6 months of screening and if all HHC screen negative for influenza infection. The main endpoints are assessed based on multiple respiratory swabs obtained from both IP and HHC up to 9 (+/-1) days post IP randomization.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Baloxavir Marboxil

Condition Name

Condition Name for Baloxavir Marboxil
Intervention Trials
Influenza 6
Respiratory Viral Infection 1
Hematopoietic and Lymphoid Cell Neoplasm 1
Healthy Volunteer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Baloxavir Marboxil
Intervention Trials
Influenza, Human 6
Virus Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Baloxavir Marboxil

Trials by Country

Trials by Country for Baloxavir Marboxil
Location Trials
United States 56
Ukraine 6
Brazil 6
Spain 5
Mexico 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Baloxavir Marboxil
Location Trials
Texas 5
Nebraska 3
Colorado 3
New York 3
Kentucky 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Baloxavir Marboxil

Clinical Trial Phase

Clinical Trial Phase for Baloxavir Marboxil
Clinical Trial Phase Trials
Phase 4 1
Phase 3 4
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Baloxavir Marboxil
Clinical Trial Phase Trials
Not yet recruiting 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Baloxavir Marboxil

Sponsor Name

Sponsor Name for Baloxavir Marboxil
Sponsor Trials
Hoffmann-La Roche 5
M.D. Anderson Cancer Center 1
University of Washington 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Baloxavir Marboxil
Sponsor Trials
Industry 6
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Merck
Express Scripts
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.